ClinicalTrials.gg
RecruitingNCT07417826Updated Feb 18, 2026

Cognitive-Behavioral and Digital Therapy for Suicide Risk in Eating Disorders

An interventional study of Cognitive Behavioural Therapy (CBT) and Cognitive Behavioural Therapy (CBT) + Digital Therapy (DT) in Eating Disorders and Suicide Risk, sponsored by Universitat Autonoma de Barcelona. Recruiting at 1 site in Spain. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Universitat Autonoma de Barcelona · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2025, registered Feb 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Feeding and Eating Disorders with a site in Spain — 10 open to participants now, 11 under way, none of them phase 3. Feeding and Eating Disorders · Spain.

Planned enrollment
7th of 23
150 · median 103
Started
2025
with 3 others
No phase
21 of 28
8 open now
Primary completion
2028-10
later than 9 of 10 live
Registered
22nd of 28
by date
Lead sponsor
2 of 28
Universitat Autonoma de Barcelona

Among the 28 studies in Feeding and Eating Disorders with a site in Spain, this one is the 7th largest by planned enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2025, is one of 21 with no phase, reaches primary completion later than 9 of the 10 other live ones, and was the 22nd registered.

Feeding and Eating Disorders

645 studies on the registry are indexed under Feeding and Eating Disorders; 151 are open to participants now.

Browse Feeding and Eating Disorders studies →

Open to participants now

10 of the 28 studies in Feeding and Eating Disorders with a site in Spain are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 99 Feeding and Eating Disorders studies recruiting now, 31 (31%) set no upper age limit and 66 (67%) stop at 75 or younger; 45 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Feeding and Eating Disorders with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to determine if adding a digital intervention to standard cognitive-behavioral therapy (CBT) is more effective in preventing suicide risk and reducing eating disorder symptoms. Participants will be women between 18 and 65 years old who have recently experienced suicidal ideation or attempts. One group will receive standard group therapy, while the other will receive group therapy plus a mobile application and digital monitoring devices. The goal is to see if digital tools can improve clinical outcomes and safety for patients.

03

Conditions studied

  • Eating Disorders
  • Suicide Risk
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gender: Female.
  • Age between 18 and 65 years old.
  • Clinically stable and able to provide written .
  • Subjects included in the "Suicide Risk Code" (Codi Risc Suïcidi - CRS) program due to recent suicidal ideation or suicide attempts.
  • Patients with a diagnosis of an Eating Disorder (ED).

Exclusion criteria

Exclusion Criteria:

  • Presence of intellectual disability or cognitive impairment that prevents understanding the therapy or the study requirements.
  • Diagnosis of Bipolar Disorder or any Psychotic Disorder.
  • Current active substance abuse or dependence.
  • Any medical condition that, in the investigator's opinion, makes participation unsafe or unfeasible.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Cognitive Behavioural Therapy (CBT) + Digital Therapy (DT)

    Behavioral: Cognitive Behavioural Therapy (CBT) + Digital Therapy (DT)

  • Active comparator
    Cognitive Behavioural Therapy (CBT)

    Behavioral: Cognitive Behavioural Therapy (CBT)

Interventions

  • BehavioralCognitive Behavioural Therapy (CBT)

    8 structured group sessions based on Christopher Fairburn's program.

  • BehavioralCognitive Behavioural Therapy (CBT) + Digital Therapy (DT)

    DigitaI therapy: includes a mobile app with a digital safety plan (warning signs, coping strategies, contact persons, etc.) activated by real-time risk assessments (2-4 random questions daily)

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Eating Attitudes Test-26 (EAT-26) Score.

    The EAT-26 is a self-report questionnaire used to assess eating disorder risk and symptoms. It consists of 26 items. Total scores range from 0 to 78, where higher scores indicate greater severity of eating disorder symptoms.

    Time frame: Baseline (Week 0), End of treatment (Week 8), 6-month follow-up, and 12-month follow-up.

  2. Change from Baseline in Bulimic Investigatory Test Edinburgh (BITE) Score.

    The BITE is used to identify individuals with binge-eating and compensatory behaviors. It consists of two subscales: Symptoms (0-30 points) and Severity (0-39 points). We will report the Total Score. Higher scores indicate higher levels of bulimic symptoms.

    Time frame: Baseline (Week 0), End of treatment (Week 8), 6-month follow-up, and 12-month follow-up.

  3. Change from Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) Score.

    The C-SSRS Full Scale is a clinical tool used to assess the full spectrum of suicidal ideation and behavior. It consists of two main sections: (1) Suicidal Ideation (A severity scale ranging from 0 (no ideation) to 5 (active suicidal ideation with specific plan and intent) and (2) Suicidal Behavior (A scale that tracks the presence of actual, interrupted, or aborted attempts, and preparatory acts rated as Yes/No). For this outcome, we will report the Suicidal Ideation Severity Score. Higher scores indicate a greater severity of suicidal ideation.

    Time frame: Baseline (Week 0), End of treatment (Week 8), 6-month follow-up, and 12-month follow-up.

Secondary outcomes

  1. Change from Baseline in Patient Health Questionnaire-9 (PHQ-9) Score.

    The PHQ-9 is a 9-item tool used to monitor the severity of depression. Scores range from 0 to 27. Higher scores indicate greater severity of depressive symptoms.

    Time frame: Baseline (Week 0), End of treatment (Week 8), 6-month follow-up, and 12-month follow-up.

  2. Change from Baseline in Generalized Anxiety Disorder-7 (GAD-7) Score.

    The GAD-7 is a 7-item scale used to measure the severity of generalized anxiety. Scores range from 0 to 21. Higher scores indicate greater severity of anxiety symptoms.

    Time frame: Baseline (Week 0), End of treatment (Week 8), 6-month follow-up, and 12-month follow-up.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2028, 36 months after the start.

Of 267 non-industry interventional studies with no phase under Feeding and Eating Disorders, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 36 months is above that.

Counting every sponsor, half of 272 studies reached it within 28 months; a quarter within 14 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Feb 18, 2026
StartActual
Oct 22, 2025
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07417826
Lead sponsor
Universitat Autonoma de Barcelona
Responsible party
Aleix Jorba Chacón (Clinical psychologist, Universitat Autonoma de Barcelona) — Principal investigator
First posted
Feb 18, 2026
Start date
Oct 22, 2025
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Feb 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion